30.07
7.84%
-2.635
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Assetmark Inc. Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
FY2024 Earnings Forecast for GPCR Issued By Lifesci Capital - Defense World
GPCRStructure Therapeutics Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan
Structure Therapeutics (NASDAQ:GPCR) Trading Down 8.9%Here's What Happened - MarketBeat
Structure Therapeutics to Present at Jefferies London Healthcare Conference | GPCR Stock News - StockTitan
GSA Capital Partners LLP Purchases Shares of 30,464 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Reports Strong Q3 2024 Results - TipRanks
Structure Therapeutics Advances Obesity Drug Trial, Reports $915M Cash Position | GPCR Stock News - StockTitan
Structure Therapeutics Launches Phase 2b Obesity Drug Trial, Expands Testing to Higher Doses | GPCR Stock News - StockTitan
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World
Is Viking Therepautics a Buy Now? - MSN
Oral Proteins and Peptides Market to Reach $28.17 Billion by 2031 As Revealed In New Report - WhaTech
Some of the Major Key Players in the oral proteins and peptides market are - InsightAce Analytic
Structure Therapeutics Inc. (NASDAQ:GPCR) Position Increased by abrdn plc - MarketBeat
Ballard Power Systems Inc (NASDAQ: BLDP) Has Great Upside Potential - Stocks Register
Is Structure Therapeutics Inc ADR (NASDAQ: GPCR) A Good Investment For New Investors Now? - Stocks Register
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
Biopharma Co. Can't Knock Ex-CFO's Bias Suit Out Of Court - Law360
Armata Pharmaceuticals Announces Structural Biology Publication - StockTitan
Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21 - Business Wire
Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $86.80 - MarketBeat
GPCR drugmaker Septerna amasses $288M in IPO - BioPharma Dive
Griffin Asset Management Inc. Acquires New Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR (GPCR) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Exchange Traded Concepts LLC Has $1.80 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR Inc. (GPCR) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Daily Progress: Structure Therapeutics Inc ADR (GPCR) Drop -1.39, Closing at 38.32 - The Dwinnex
Is Structure Therapeutics Inc ADR (GPCR) a threat to investors? - US Post News
Structure Therapeutics (NASDAQ:GPCR) Shares Down 2.7%Here's What Happened - MarketBeat
Structure Therapeutics Inc ADR: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Top investors say Structure Therapeutics Inc ADR (GPCR) ticks everything they need - SETE News
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch. - BioPharma Dive
Weight Loss Drugs Market Top Trends 2024-2031 - InsightAce Analytic
Market Recap Check: Structure Therapeutics Inc ADR (GPCR)’s Positive Finish at 40.50, Up/Down 0.30 - The Dwinnex
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? - Yahoo Finance
Structure Therapeutics (NASDAQ:GPCR) Shares Up 3.7%Here's What Happened - MarketBeat
The Manufacturers Life Insurance Company Buys 32,839 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR (GPCR) is a good investment, but the stock may be overvalued - US Post News
27,094 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Bank of Montreal Can - MarketBeat
35,700 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Renaissance Technologies LLC - Defense World
Marshall Wace LLP Raises Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
3 AI Stocks to Buy as Nvidia Sputters - InvestorPlace
Are Structure Therapeutics Inc ADR (GPCR) shares a good deal now? - US Post News
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety - Yahoo Finance
Structure Therapeutics (NASDAQ:GPCR) Trading 5.8% Higher - MarketBeat
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer - BioSpace
Nasdaq Global Select Market Composite Index (NQGS) QuotePress Release - The Globe and Mail
S&P 100 Index (OEX) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
Ratios Uncovered: Breaking Down Structure Therapeutics Inc ADR (GPCR)’s Trailing Twelve Months Metrics - The Dwinnex
Structure Therapeutics Inc ADR (GPCR) expanding its growth trajectory ahead - SETE News
Perceptive Advisors LLC Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Perceptive Advisors LLC Acquires Shares of 34,852 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics' SWOT analysis: small-cap biotech's stock potential in obesity market - Investing.com
18,803 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Purchased by Scientech Research LLC - MarketBeat
Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now? - Insider Monkey
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):